Acurx Pharma Advances Antibiotic Program Toward Phase 3 C. diff Trials | NewsOut

Biotech and healthcare investors: Acurx Pharmaceuticals reported key financial and operational highlights from 2025 and early 2026 as the company advances development of a new class of antibiotics targeting difficult-to-treat bacterial infections.

Reporting from the New York Stock Exchange, Jane King explains the company presented its antimicrobial pipeline at IDWeek, published collaborative research with Leiden University Medical Center in Nature Communications, and launched a new clinical trial program for recurrent C. difficile infection as it prepares to advance toward Phase 3 international trials.

#AcurxPharmaceuticals
#AntibioticDevelopment
#Cdiff
#ClinicalTrials
#BiotechNews
#InfectiousDisease
#DrugDevelopment
#MedicalResearch
#HealthcareInnovation
#BiotechInvesting
#JaneKing
#NewsOut